Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Soheil Meshinchi

Showing results (131-140 of 218) with videos related to

Pageof 22
Sort By:
Cancer Research Communications|September 8, 2025
Preclinical Evaluation of Folate Receptor-α Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against OsteosarcomaMichelle Choe, Danielle Kirkey, Isabel Lira, et al.
Blood Advances|January 23, 2023
SAMHD1 single nucleotide polymorphisms impact outcome in children with newly diagnosed acute myeloid leukemiaRichard J Marrero, Xueyuan Cao, Huiyun Wu, et al.
Proteomics. Clinical Applications|November 1, 2021
Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-κB subunit RelAAnneke D van Dijk, Fieke W Hoff, Yihua Qiu, et al.
American Journal of Hematology|May 21, 2013
Significance of expression of ITGA5 and its splice variants in acute myeloid leukemia: a report from the Children's Oncology GroupRoland B Walter, George S Laszlo, Todd A Alonzo, et al.
Pediatric Blood & Cancer|February 15, 2023
Pathologic, cytogenetic, and molecular features of acute myeloid leukemia with megakaryocytic differentiation: A report from the Children's Oncology GroupKaren M Chisholm, Jenny Smith, Amy E Heerema-McKenney, et al.
Biorxiv : the Preprint Server for Biology|April 8, 2025
<i>TP53</i> Inactivation Confers Resistance to the Menin Inhibitor Revumenib in Acute Myeloid LeukemiaJeevitha D'Souza, Camille J Leung, Aishwarya C Ballapuram, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 6, 2014
Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531Alan S Gamis, Todd A Alonzo, Soheil Meshinchi, et al.
JAMA Oncology|November 11, 2021
Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report From the Children's Oncology Group AAML1331 TrialMatthew A Kutny, Todd A Alonzo, Oussama Abla, et al.
Plos One|August 23, 2013
The prognostic significance of IRF8 transcripts in adult patients with acute myeloid leukemiaEra L Pogosova-Agadjanyan, Kenneth J Kopecky, Fabiana Ostronoff, et al.
Blood Advances|February 2, 2024
Structural variants involving MLLT10 fusion are associated with adverse outcomes in pediatric acute myeloid leukemiaOussama Abla, Rhonda E Ries, Tim Triche, et al.
Pageof 22

Showing results (131-140 of 218) with videos related to

Sort By:
Pageof 22
Cancer Research Communications|September 8, 2025
Preclinical Evaluation of Folate Receptor-α Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against OsteosarcomaMichelle Choe, Danielle Kirkey, Isabel Lira, et al.
Blood Advances|January 23, 2023
SAMHD1 single nucleotide polymorphisms impact outcome in children with newly diagnosed acute myeloid leukemiaRichard J Marrero, Xueyuan Cao, Huiyun Wu, et al.
Proteomics. Clinical Applications|November 1, 2021
Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-κB subunit RelAAnneke D van Dijk, Fieke W Hoff, Yihua Qiu, et al.
American Journal of Hematology|May 21, 2013
Significance of expression of ITGA5 and its splice variants in acute myeloid leukemia: a report from the Children's Oncology GroupRoland B Walter, George S Laszlo, Todd A Alonzo, et al.
Pediatric Blood & Cancer|February 15, 2023
Pathologic, cytogenetic, and molecular features of acute myeloid leukemia with megakaryocytic differentiation: A report from the Children's Oncology GroupKaren M Chisholm, Jenny Smith, Amy E Heerema-McKenney, et al.
Biorxiv : the Preprint Server for Biology|April 8, 2025
<i>TP53</i> Inactivation Confers Resistance to the Menin Inhibitor Revumenib in Acute Myeloid LeukemiaJeevitha D'Souza, Camille J Leung, Aishwarya C Ballapuram, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 6, 2014
Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531Alan S Gamis, Todd A Alonzo, Soheil Meshinchi, et al.
JAMA Oncology|November 11, 2021
Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report From the Children's Oncology Group AAML1331 TrialMatthew A Kutny, Todd A Alonzo, Oussama Abla, et al.
Plos One|August 23, 2013
The prognostic significance of IRF8 transcripts in adult patients with acute myeloid leukemiaEra L Pogosova-Agadjanyan, Kenneth J Kopecky, Fabiana Ostronoff, et al.
Blood Advances|February 2, 2024
Structural variants involving MLLT10 fusion are associated with adverse outcomes in pediatric acute myeloid leukemiaOussama Abla, Rhonda E Ries, Tim Triche, et al.
Pageof 22